Source: Aastrom Biosciences, Inc.
Date: April 30, 2007
Summary:
Aastrom Biosciences, Inc. (Nasdaq:ASTM), a regenerative medicine company, today announced that it has initiated its U.S. Phase IIb prospective, controlled, randomized, double-blind, multi-center clinical trial to treat patients suffering from peripheral arterial disease (PAD), a chronic disease that progressively restricts blood flow in the limbs and can lead to serious medical complications.
